Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24363831 | 0.82 | AURKA (0.37) | PIK3CAHTTPIK3CDPIK3CBPIK3CG | |
| SCHEMBL30469696 | 0.81 | GPR119 (0.32) | — | |
| SCHEMBL24366391 | 0.81 | GPR119 (0.32) | — | |
| SCHEMBL24363778 | 0.80 | NPC1 (0.39) | — | |
| SCHEMBL29477715 | 0.80 | NPC1 (0.39) | — | |
| SCHEMBL31136486 | 0.80 | NPC1 (0.39) | — | |
| SCHEMBL30551053 | 0.80 | CYP1A2 (0.35) | — | |
| SCHEMBL25320071 | 0.80 | CYP1A2 (0.35) | — | |
| SCHEMBL25320075 | 0.80 | CYP1A2 (0.35) | — | |
| SCHEMBL31266462 | 0.80 | KDM4E (0.36) | PIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | STK17B 4200/4885SSTR4 864/4885PIK3CA 3586/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | STK17B 4200/4885SSTR4 864/4885PIK3CA 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.